Gilead Sciences (GILD) ended the recent trading session at $91.86, demonstrating a -0.57% swing from the preceding day's closing price. On the other hand, the Dow registered a loss of 0.2%, and the ...
A review found half of the drugs studied had price increases based on new evidence of benefits, while the other half did not.
The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...
In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.
El Mundo on MSN19h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human ...
Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...
CC is on patient advisory councils for GSK and Gilead Sciences, paid to the Hepatitis B Foundation. SF has received a research grant from British HIV Association–Gilead Sciences; has received ...
He joins Gilead at a good tiem for the company. The drugmaker saw a 22% boost in market cap over Q3, benefitting from ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback